- Home
- CLDI vs LSTA Comparison
CLDI vs LSTA Comparison
Compare CLDI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- LSTA
- Stock Information
- Founded
- CLDI 2014
- LSTA 1980
- Country
- CLDI United States
- LSTA United States
- Employees
- CLDI N/A
- LSTA N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- LSTA Misc Health and Biotechnology Services
- Sector
- CLDI Health Care
- LSTA Health Care
- Exchange
- CLDI Nasdaq
- LSTA Nasdaq
- Market Cap
- CLDI 20.2M
- LSTA 22.3M
- IPO Year
- CLDI N/A
- LSTA N/A
- Fundamental
- Price
- CLDI $1.60
- LSTA $2.15
- Analyst Decision
- CLDI
- LSTA Strong Buy
- Analyst Count
- CLDI 0
- LSTA 2
- Target Price
- CLDI N/A
- LSTA $23.50
- AVG Volume (30 Days)
- CLDI 484.3K
- LSTA 21.9K
- Earning Date
- CLDI 11-11-2025
- LSTA 11-11-2025
- Dividend Yield
- CLDI N/A
- LSTA N/A
- EPS Growth
- CLDI N/A
- LSTA N/A
- EPS
- CLDI N/A
- LSTA N/A
- Revenue
- CLDI N/A
- LSTA $1,070,000.00
- Revenue This Year
- CLDI N/A
- LSTA N/A
- Revenue Next Year
- CLDI N/A
- LSTA N/A
- P/E Ratio
- CLDI N/A
- LSTA N/A
- Revenue Growth
- CLDI N/A
- LSTA N/A
- 52 Week Low
- CLDI $1.51
- LSTA $1.87
- 52 Week High
- CLDI $46.68
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- CLDI 30.60
- LSTA 38.47
- Support Level
- CLDI $1.51
- LSTA $2.11
- Resistance Level
- CLDI $1.68
- LSTA $2.33
- Average True Range (ATR)
- CLDI 0.10
- LSTA 0.16
- MACD
- CLDI 0.14
- LSTA -0.01
- Stochastic Oscillator
- CLDI 22.97
- LSTA 14.81
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.